An observational study in Severe Sepsis, Septic Shock and Acute Kidney Injury, sponsored by Sygehus Lillebaelt. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-21.
Sponsored by Sygehus Lillebaelt · Observational
Patients with severe infection and sepsis are in high risk of hypo perfusion and therefore organ affection. Temporary or permanent kidney failure is a common complication in these patients. Today's golden standard for kidney failure detection is creatinine levels rising and / or oliguria. The investigators hypothesize that an even more sensitive biomarker; neutrophil gelatinase associated lipocalin(NGAL) in urine can predict kidney injury before creatinine levels rise. In recent studies NGAL in urine seem to be a sensitive biomarker in these patient to predict kidney injury, but the time factor for sampling optimally is not known. In this pilot study the investigators sample the urine at admission within the first hour of hospitalization to investigate if NGAL can be used as a predictor in an emergency setting.
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's enrollment of 21 is below the median of 160 across 931 observational studies indexed under Sepsis.
Browse Sepsis studies →Sygehus Lillebaelt is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults with no prior record of kidney failure
Exclusion Criteria:
Development of Acute Kidney Failure
Time frame: During hospitalization, anticipated approximately 5 weeks
Levels of NGAL in patients with kidney failure compared to creatinine
Time frame: During hospitalization, anticipated approximately 5 weeks
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sygehus Lillebaelt